PHARMACOKINETICS AND DRUG DISPOSITION St John’s Wort: Effect on CYP3A4 activity
暂无分享,去创建一个
E. Kantor | Carol A. Roby | Gail D. Anderson | Donna A. Dryer | Aaron H. Burstein | Aaron H. Burstein | Gail D. Anderson | Donna A. Dryer
[1] F. Ruschitzka,et al. Acute heart transplant rejection due to Saint John's wort , 2000, The Lancet.
[2] S. Risch,et al. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. , 2000, Life sciences.
[3] E. Ernst,et al. Second thoughts about safety of St John's wort , 1999, The Lancet.
[4] I. Roots,et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) , 1999, Clinical pharmacology and therapeutics.
[5] T. Rebbeck. Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4 , 1999 .
[6] P. Hopkins,et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4 , 1999, Clinical pharmacology and therapeutics.
[7] S. J. Kovacs,et al. Morning Spot and 24‐Hour Urinary 6β‐Hydroxycortisol to Cortisol Ratios: Intraindividual Variability and Correlation under Basal Conditions and Conditions of CYP 3A4 Induction , 1999, Journal of clinical pharmacology.
[8] D. Kroll,et al. Potential Metabolic Interaction between St. John's Wort and Theophylline , 1999, The Annals of pharmacotherapy.
[9] M J Cupp,et al. Herbal remedies: adverse effects and drug interactions. , 1999, American family physician.
[10] R. Tackett,et al. St. John's wort: a new alternative for depression? , 1999, International journal of clinical pharmacology and therapeutics.
[11] M. Klepser,et al. Unsafe and potentially safe herbal therapies. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[12] S. London,et al. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. , 1998, Pharmacogenetics.
[13] D. Smith,et al. Human cytochrome P450s: selectivity and measurement in vivo. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[14] A. Burstein,et al. Cytochrome P450 3A4 Activity in Premenopausal and Postmenopausal Women, Based on 6‐β‐Hydroxycortisol:Cortisol Ratios , 1998, Pharmacotherapy.
[15] H. Boon,et al. Herbal remedies in psychiatric practice. , 1998, Archives of general psychiatry.
[16] J. Chaffin,et al. Herbal 'health' products: what family physicians need to know. , 1998, American family physician.
[17] D. Jorkasky,et al. Urinary excretion of 6β‐hydroxycortisol as an in vivo marker for CYP3A induction: Applications and recommendations , 1998, Clinical pharmacology and therapeutics.
[18] E. Heiligenstein,et al. Over-the-counter psychotropics: a review of melatonin, St John's wort, valerian, and kava-kava. , 1998, Journal of American college health : J of ACH.
[19] Elizabeth Landrum Michalets,et al. Update: Clinically Significant Cytochrome P‐450 Drug Interactions , 1998, Pharmacotherapy.
[20] B C Eliason,et al. Dietary Supplement Users: Demographics, Product Use, and Medical System Interaction , 1997, The Journal of the American Board of Family Medicine.
[21] J. Brockmöller,et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin , 1996, Antimicrobial agents and chemotherapy.
[22] P. D. Smet. Health Risks of Herbal Remedies , 1995 .
[23] T. Bienvenu,et al. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. , 1991, International journal of clinical pharmacology, therapy, and toxicology.
[24] S. Wrighton,et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.
[25] P. Beaune,et al. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. , 1989, British journal of clinical pharmacology.
[26] P. Watkins,et al. Identification of a polymorphically expressed member of the human cytochrome P-450III family. , 1989, Molecular pharmacology.
[27] G. Zaccara,et al. Urinary 6-beta-OH-cortisol and paracetamol metabolites as a probe for assessing oxidation and conjugation of chemicals in humans. , 1987, Pharmacological research communications.
[28] P. Saenger. 6β‐Hydroxycortisol in random urine samples as an indicator of enzyme induction , 1983 .
[29] L. Harries,et al. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. , 1998, Xenobiotica; the fate of foreign compounds in biological systems.
[30] H. Hippius. St John's Wort (Hypericum perforatum)--a herbal antidepressant. , 1998, Current medical research and opinion.
[31] U. Mansmann,et al. Urinary 6 beta-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment. , 1997, International journal of clinical pharmacology and therapeutics.
[32] P. D. de Smet. Health risks of herbal remedies. , 1995, Drug safety.